[1]杨 俊,印 于,张 申,等.HAIC序贯TAE治疗不可切除肝细胞癌的安全性和有效性[J].介入放射学杂志,2023,32(03):229-232.
 YANG Jun,YIN Yu,ZHANG Shen,et al.The safety and efficacy of sequential hepatic arterial infusion chemotherapy and transarterial embolization for unresectable hepatocellular carcinoma[J].journal interventional radiology,2023,32(03):229-232.
点击复制

HAIC序贯TAE治疗不可切除肝细胞癌的安全性和有效性()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
32
期数:
2023年03
页码:
229-232
栏目:
肿瘤介入
出版日期:
2023-03-31

文章信息/Info

Title:
The safety and efficacy of sequential hepatic arterial infusion chemotherapy and transarterial embolization for unresectable hepatocellular carcinoma
作者:
杨 俊 印 于 张 申 朱晓黎 倪才方 仲斌演 周帮健 王万胜
Author(s):
YANG Jun YIN Yu ZHANG Shen ZHU Xiaoli NI Caifang ZHONG Binyan ZHOU Bangjian WANG Wansheng.
Department of Interventional Radiology, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province 215000, China
关键词:
【关键词】 肝动脉灌注化疗 肝动脉栓塞 肝细胞癌 不良反应
文献标志码:
A
摘要:
【摘要】 目的 评估肝动脉灌注化疗(HAIC)序贯肝动脉栓塞术(TAE)治疗不可切除肝细胞癌的安全性及有效性。方法 收集2020年4月至2021年4月采用HAIC序贯TAE治疗的25例肝癌患者的临床资料,以ALBI评分评估患者肝功能变化情况,记录术后出现的不良反应。根据改良实体瘤疗效评价标准(mRECIST)评估肿瘤客观缓解率(ORR)、疾病控制率(DCR),并随访患者的疾病进展时间(TTP)和生存时间(OS)。结果 患者首次治疗后3个月ALBI评分(-2.29±0.53)与术前(-2.32±0.44)相比,差异无统计学意义(t=-0.223,P=0.825)。主要不良反应包括肝功能损伤、骨髓抑制、腹痛、恶心呕吐、发热等,4例患者出现Ⅲ级不良反应(3例ALT升高,1例骨髓抑制),其余均为Ⅰ~Ⅱ级不良反应。术后6周ORR、DCR分别为68%、92%,术后12周ORR、DCR分别为72%、88%,中位TTP为271 d(95%CI:115.9~426.0),中位OS为510 d(95%CI:491.5~528.5)。结论 HAIC序贯TAE治疗不可切除肝癌临床疗效显著,具有良好的耐受性,是安全可行的。

参考文献/References:

[1] 中国医师协会介入医师分会临床诊疗指南专委会. 中国肝细胞癌经动脉化疗栓塞(TACE)治疗临床实践指南(2021年版)[J]. 中华医学杂志, 2021, 101:1848-1862.
[2] Tsurusaki M, Murakami T, et al. Surgical and locoregional therapy of HCC: TACE[J]. Liver Cancer, 2015, 4: 165-175.
[3] Guo W,Gao J,Zhuang W,et al. Efficacy and safety of hepatic arterial infusion chemotherapy combined with transarterial embolization for unresectable hepatocellular carcinoma: a propensity score-matching cohort study[J]. JGH Open, 2020, 4: 477- 483.
[4] 吴孟超,汤钊猷,刘允怡,等. 原发性肝癌诊疗规范(2019年版) [J]. 中国实用外科杂志, 2020, 40:121-138.
[5] Zhao X, Sun X, Jing J, et al. Safety study of Folfox-HAIC in relieving bed restriction[J]. J Interv Med, 2021, 4: 203-207.
[6] Qin S, Bai Y, Lim HY, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J]. J Clin Oncol, 2013, 31: 3501-3508.
[7] Zhuang BW,Li W,Xie XH,et al. Sorafenib versus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a systematic review and meta- analysis[J]. Jpn J Clin Oncol, 2019, 49: 845-855.
[8] Fu Z,Li X,Zhong J,et al. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma(uHCC): a retrospective controlled study[J]. Hepatol Int, 2021, 15: 663-675.
[9] Chen S,Yu W,Zhang K,et al. Comparison of the efficacy and safety of conventional transarterial chemoembolization with and without drug- eluting beads embolization for the treatment of unresectable large hepatocellular carcinoma[J]. Hepatol Res, 2021, 51: 482- 489.
[10] Lencioni R,de Baere T,Soulen MC,et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data[J]. Hepatology, 2016, 64: 106-116.
[11] 魏庭丰,何仕诚,朱海东,等. 原发性肝癌肝动脉化疗栓塞治疗间隔长短对近期肝功能影响的比较[J]. 介入放射学杂志, 2020, 29:1126-1130.
[12] He M,Li Q,Zou R,et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial[J]. JAMA Oncol, 2019, 5: 953-960.
[13] Li S,Lyu N,Han X,et al. Hepatic artery infusion chemotherapy using fluorouracil, leucovorin, and oxaliplatin versus transarterial chemoembolization as initial treatment for locally advanced hepatocellular carcinoma: a propensity score- matching analysis[J]. J Vasc Interv Radiol, 2021, 32: 1267-1276.

相似文献/References:

[1]王邦浩.影响肝癌介入治疗效果的因素及对策[J].介入放射学杂志,1998,(03):170.
[2]曾晓华,王颂章,郑湖民,等.经肝动脉灌注化疗并栓塞治疗肝恶性肿瘤的质量保证[J].介入放射学杂志,1999,(01):57.
[3]吴纪瑞,杨永岩,杨熙章,等.丝裂霉素C微囊肝动脉化疗栓塞术治疗中晚期肝癌[J].介入放射学杂志,1992,(01):41.
[4]田建明,孙飞,叶华,等.医源性肝动脉瘤9例报告[J].介入放射学杂志,1992,(01):39.
[5]卢小军,吴锦章,朱松英,等.肝动脉化疗并栓塞治疗肝癌并发急性胰腺炎2例[J].介入放射学杂志,1993,(01):28.
[6]吴建安,李留保,王永增,等.基层医院开展介入放射学的几点体会[J].介入放射学杂志,1994,(01):2.
[7]吴驰,王建华,颜志平,等.脾动脉栓塞治疗肝癌合并脾亢的应用观察[J].介入放射学杂志,1994,(01):48.
[8]陈庆华.肝动脉栓塞微球对移植型肝癌大鼠疗效的实验研究[J].介入放射学杂志,1994,(02):93.
[9]夏晓,陆进.经腹腔动脉门脉造影:门脉高压32例分析[J].介入放射学杂志,1994,(02):101.
[10]陈岳声.肝动脉栓塞与化栓的并发症:治疗和预防[J].介入放射学杂志,1994,(03):175.

备注/Memo

备注/Memo:
(收稿日期:2022- 06- 01)
(本文编辑:新 宇)
更新日期/Last Update: 2023-03-28